Menu
← Oncology Approval Tracker
FDA DECISION ·
Orencia
abatacept with a calcineurin inhibitor and methotrexate · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Prophylaxis of acute graft-versus-host disease for patients age 2 and older undergoing hematopoietic stem cell transplantation from a matched or one-allele-mismatched unrelated donor.
LAMPGEN ANALYSIS
Why it matters
The label adds abatacept to a prophylactic regimen for a defined unrelated-donor transplant population.
What research teams should watch
Confirm donor match, transplant dates and concomitant prophylaxis, and follow post-transplant infection monitoring.
PRIMARY RECORDS